Microbix Biosystems Inc.

As of June 30, 2026, Microbix Biosystems Inc. carries a market capitalization of 41.17M, placing it among publicly traded companies globally. Its enterprise value stands at 40.73M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Microbix Biosystems Inc.'s next confirmed earnings release is scheduled for December 17, 2026.

As of June 30, 2026, Microbix Biosystems Inc. has 137.25M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.70, and the price-to-book ratio stands at 1.70.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.65 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 40.73M versus a market cap of 41.17M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Microbix Biosystems Inc. maintains a current ratio of 6.89, meaning it holds 6.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 27.69, indicating elevated leverage, while an interest coverage ratio of -2.38 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Microbix Biosystems Inc. posted a negative return on equity (ROE) of -18.24, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -13.51, reflecting losses generated across the asset base. The company generates approximately 220,003.40 in revenue per employee across its workforce of 70.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.86 indicates how many times Microbix Biosystems Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 21, 2026, Microbix Biosystems Inc.'s stock has gained approximately 30.61% over the past 52 weeks. The 50-day moving average sits at 0.30, while the 200-day moving average is 0.27.

Over the twelve months ended June 30, 2026, Microbix Biosystems Inc. generated 15.40M in revenue and converted that into -4.88M in net income, yielding earnings per share of -0.04. EBITDA reached -2.41M, while operating income came in at -4.28M.

As of June 30, 2026, Microbix Biosystems Inc. holds 7.16M in cash and equivalents against 6.72M in total debt, resulting in a net debt position of -1.80M. Total book value stands at 24.26M, with working capital of 18.09M providing operational flexibility.

Microbix Biosystems Inc. produced -3.29M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -595,172.00 in capital expenditures, free cash flow totaled -3.89M - equivalent to -0.03 per share.

Over the twelve months ended June 30, 2026, Microbix Biosystems Inc. posted a gross margin of 45.90, reflecting its pricing power and cost economics. The operating margin of -27.77 and net profit margin of -31.72 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -9.35: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 2.56, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Microbix Biosystems Inc. shareholders.

As of June 30, 2026, Microbix Biosystems Inc. has an Altman Z-Score of 1.49, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.